modelEptifibatide
Extends from Pharmacolibrary.Drugs.ATC.B.B01AC16.
Information
| name: | Eptifibatide | |
| ATC code: | B01AC16 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 180 | mg |
| volume of distribution: | 185 | L |
| clearance: | 55 | L/h |
| other parameters in model implementation | ||
Eptifibatide is a cyclic heptapeptide antiplatelet drug, classified as a glycoprotein IIb/IIIa receptor antagonist. It is used to reduce the risk of acute cardiac ischemic events, such as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Eptifibatide is approved and in clinical use for this indication.
Pharmacokinetics
Mean pharmacokinetic parameters in adults with coronary artery disease undergoing PCI, male and female, typical intravenous administration.
References
Liu, L, et al., & Zhang, H (2020). Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects. Clinical pharmacology in drug development 9(2) 267–276. DOI:10.1002/cpdd.717 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31197974
Gretler, DD (2003). Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clinical therapeutics 25(10) 2564–2574. DOI:10.1016/s0149-2918(03)80317-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14667957
Zhou, ZL, et al., & Lin, SG (2010). Improved liquid chromatography-tandem mass spectrometry method for the analysis of eptifibatide in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878(23) 2094–2100. DOI:10.1016/j.jchromb.2010.06.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20599442
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)